Stock listing
BOATS:SPRC SciSparc Ltd. Stock
US listing (BOATS) of SciSparc Ltd. · home listing NASDAQ:SPRC
Follow SciSparc Ltd. into a list and get an email when it puts out news.
Home listing price · NASDAQ:SPRC
$0.196 USD -0.104 (-34.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SPRC
- Day range
- $0.167 – $0.262 USDNov 20, 2026
- Volume
- 4.55M sharesNov 20, 2026
- Market cap
- —Left out: price × shares is far from the company's reported size
- 52-week range
- $0.167 – $29.880 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.51M USDMedian day 49,950 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SPRC · Home | $0.196 USD | -0.104 (-34.7%) | 4,553,200 | $0.257 | $0.262 | $0.167 | $0.300 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SPRC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.196 | -0.104 | -34.7% | $0.257 | $0.262 | $0.167 | 4,553,200 | |
| $0.300 | +0.030 | +11.1% | $0.321 | $0.390 | $0.270 | 79,662,700 | |
| $0.270 | -0.060 | -18.2% | $0.358 | $0.369 | $0.228 | 16,816,600 | |
| $0.330 | -0.001 | -0.3% | $0.330 | $0.350 | $0.307 | 78,900 | |
| $0.331 | -0.022 | -6.2% | $0.354 | $0.373 | $0.330 | 64,900 | |
| $0.353 | -0.002 | -0.6% | $0.359 | $0.370 | $0.345 | 50,600 | |
| $0.355 | -0.043 | -10.8% | $0.398 | $0.403 | $0.350 | 77,900 | |
| $0.398 | +0.019 | +5.0% | $0.378 | $0.407 | $0.373 | 137,300 | |
| $0.379 | -0.037 | -8.9% | $0.386 | $0.415 | $0.372 | 170,000 | |
| $0.416 | -0.003 | -0.7% | $0.430 | $0.442 | $0.377 | 246,000 | |
| $0.419 | -0.010 | -2.3% | $0.430 | $0.440 | $0.412 | 66,300 | |
| $0.429 | -0.084 | -16.4% | $0.490 | $0.506 | $0.409 | 276,900 | |
| $0.513 | -0.086 | -14.4% | $0.571 | $0.585 | $0.507 | 228,800 | |
| $0.599 | +0.001 | +0.2% | $0.598 | $0.624 | $0.540 | 149,400 | |
| $0.598 | -0.078 | -11.5% | $0.676 | $0.676 | $0.550 | 223,900 | |
| $0.676 | -0.036 | -5.1% | $0.677 | $0.684 | $0.603 | 378,100 | |
| $0.712 | -0.118 | -14.2% | $0.796 | $0.830 | $0.680 | 593,000 | |
| $0.830 | -0.020 | -2.4% | $0.800 | $0.874 | $0.739 | 547,100 | |
| $0.850 | -0.440 | -34.1% | $0.860 | $0.948 | $0.732 | 1,940,000 | |
| $1.290 | +0.200 | +18.3% | $1.595 | $1.780 | $1.170 | 38,366,600 | |
| $1.090 | -0.110 | -9.2% | $1.210 | $1.210 | $1.070 | 6,004,400 | |
| $1.200 | -0.140 | -10.4% | $1.290 | $1.400 | $1.180 | 462,000 | |
| $1.340 | +0.010 | +0.8% | $1.340 | $1.362 | $1.310 | 51,600 | |
| $1.330 | -0.070 | -5.0% | $1.340 | $1.380 | $1.210 | 99,400 | |
| $1.400 | -0.300 | -17.6% | $1.630 | $1.720 | $1.400 | 216,900 | |
| $1.700 | -0.300 | -15.0% | $1.770 | $1.970 | $1.600 | 385,400 | |
| $2.000 | -1.630 | -44.9% | $4.200 | $5.330 | $1.630 | 34,767,400 | |
| $3.630 | -0.310 | -7.9% | $3.730 | $3.730 | $3.590 | 12,400 | |
| $3.940 | -0.140 | -3.4% | $4.030 | $4.170 | $3.895 | 22,100 | |
| $4.080 | -0.390 | -8.7% | $4.470 | $4.470 | $4.050 | 10,400 | |
| $4.470 | +0.040 | +0.9% | $4.472 | $4.600 | $4.290 | 4,800 | |
| $4.430 | -0.210 | -4.5% | $4.440 | $4.499 | $4.340 | 6,000 | |
| $4.640 | +0.310 | +7.2% | $4.400 | $4.700 | $4.400 | 40,800 | |
| $4.330 | -0.030 | -0.7% | $4.400 | $4.463 | $4.200 | 6,200 | |
| $4.360 | -0.360 | -7.6% | $4.520 | $4.600 | $4.300 | 14,300 | |
| $4.720 | +0.170 | +3.7% | $4.567 | $4.900 | $4.500 | 2,900 | |
| $4.550 | -0.170 | -3.6% | $4.547 | $4.550 | $4.547 | 1,500 | |
| $4.720 | +0.015 | +0.3% | $4.610 | $4.830 | $4.600 | 12,200 | |
| $4.705 | -0.205 | -4.2% | $4.910 | $4.930 | $4.596 | 15,800 | |
| $4.910 | -0.300 | -5.8% | $5.210 | $5.210 | $4.910 | 6,500 | |
| $5.210 | -0.180 | -3.3% | $5.276 | $5.310 | $5.210 | 8,900 | |
| $5.390 | +0.380 | +7.6% | $4.880 | $5.600 | $4.880 | 97,400 | |
| $5.010 | +0.440 | +9.6% | $4.670 | $5.510 | $4.392 | 103,900 | |
| $4.570 | +0.040 | +0.9% | $4.630 | $4.700 | $4.500 | 4,600 | |
| $4.530 | +0.020 | +0.4% | $4.643 | $4.643 | $4.450 | 4,700 | |
| $4.510 | +0.060 | +1.3% | $4.480 | $4.640 | $4.450 | 3,000 | |
| $4.450 | -0.230 | -4.9% | $5.189 | $5.189 | $4.390 | 23,900 | |
| $4.680 | -0.080 | -1.7% | $4.880 | $4.880 | $4.650 | 9,600 | |
| $4.760 | -0.150 | -3.1% | $5.140 | $5.140 | $4.720 | 12,600 | |
| $4.910 | -0.170 | -3.3% | $4.960 | $5.080 | $4.900 | 5,000 | |
| $5.080 | +0.130 | +2.6% | $5.270 | $5.270 | $5.000 | 11,600 | |
| $4.950 | 0.000 | 0.0% | $4.830 | $5.180 | $4.830 | 15,300 | |
| $4.950 | -0.150 | -2.9% | $5.110 | $5.110 | $4.950 | 17,000 | |
| $5.100 | -0.190 | -3.6% | $5.180 | $5.350 | $5.060 | 7,000 | |
| $5.290 | +0.160 | +3.1% | $5.170 | $5.435 | $5.150 | 27,700 | |
| $5.130 | -0.720 | -12.3% | $5.610 | $5.947 | $5.070 | 41,200 | |
| $5.850 | +0.180 | +3.2% | $5.800 | $6.000 | $5.410 | 49,300 | |
| $5.670 | -0.960 | -14.5% | $6.062 | $6.220 | $5.500 | 90,100 | |
| $6.630 | +0.050 | +0.8% | $6.680 | $6.880 | $6.500 | 62,500 | |
| $6.580 | -0.040 | -0.6% | $6.750 | $6.820 | $6.500 | 84,100 | |
| $6.620 | -0.120 | -1.8% | $6.690 | $6.775 | $6.540 | 11,300 | |
| $6.740 | +0.050 | +0.7% | $6.665 | $7.190 | $6.600 | 13,900 | |
| $6.690 | +0.030 | +0.5% | $6.620 | $6.855 | $6.610 | 7,200 | |
| $6.660 | -0.035 | -0.5% | $6.920 | $7.039 | $6.525 | 11,400 | |
| $6.695 | +0.070 | +1.1% | $6.500 | $6.810 | $6.500 | 3,200 | |
| $6.625 | -0.235 | -3.4% | $6.860 | $6.900 | $6.500 | 56,200 |
Splits
3 splits since 2023 · NASDAQ:SPRC · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-9 | Consolidation | |
| 1-for-21 | Consolidation | |
| 1-for-26 | Consolidation |
- Ticker
- BOATS:SPRC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
SciSparc: Former National Security Advisor to Prime Minister Benjamin Netanyahu Renowned AI Prof. Jacob Nagel Joins the Company’s SAB
Latest news
SciSparc: Former National Security Advisor to Prime Minister Benjamin Netanyahu Renowned AI Prof. Jacob Nagel Joins the Company’s SAB
Nov 16, 2026
Closed $0.331 (-6.2%) on Nov 16, 2026
SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
Oct 22, 2026
Closed $1.20 (-10.4%) on Oct 22, 2026
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
Oct 19, 2026
Closed $1.40 (-17.6%) on Oct 19, 2026
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
Oct 15, 2026
Closed $2.00 (-44.9%) on Oct 15, 2026
SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture
Oct 7, 2026
Closed $4.64 (+7.2%) on Oct 7, 2026
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
Sep 23, 2026
Closed $5.01 (+9.6%) on Sep 23, 2026
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
Sep 2, 2026
Closed $5.13 (-12.3%) on Sep 3, 2026
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
Aug 31, 2026
Closed $5.67 (-14.5%) on Sep 1, 2026
SciSparc Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 33 in the last 12 months · 167 in all · newest Nov 16, 2026 · oldest 2021
- Decks
- 10 decks · latest Oct 18, 2023
Where SciSparc Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SPRC · Home listing | NASDAQ | United States | USD |
| BOATS:SPRC · This page | BOATS | United States | USD |
Valuation
price Nov 20, 2026
- Enterprise value
- No market cap
- P/E
- No market cap
- EV/sales
- No market cap
- EV/EBITDA
- No market cap
- Price/book
- No market cap
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 1.31
Team and board
Officers
| Officer | Role |
|---|---|
| Oz Adler | Chief Executive Officer and Chief Financial Officer |
| Itschak Shrem | President |
Board
| Director | Role |
|---|---|
| Amitay Weiss | Chairman |
| Alon Dayan | external director |
| Amnon Ben Shay | external director |
| Itschak Shrem | President |
| Liat Sidi | |
| Lior Vider | |
| Moshe Revach | |
| Oz Adler | Chief Executive Officer and Chief Financial Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2025 | Apr 24, 2025 | −0.3% |
| Quarter to Sep 30, 2024 | Nov 4, 2024 | −1.3% |
| Quarter to Mar 31, 2021 | Jun 30, 2021 | |
| Quarter to Dec 31, 2020 | Mar 31, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2023) | Investor deck | 23 slides | Oct 18, 2023 |
| Investor Presentation (February 2022) | Investor deck | 22 slides | February 2022 |
| Investor Presentation (February 2021) | Investor deck | 23 slides | February 2021 |
| Therapix Biosciences — IPO Roadshow (November 2020) | IPO roadshow | 24 slides | Nov 5, 2020 |
| Therapix Biosciences — IPO Roadshow (October 2020) | IPO roadshow | 24 slides | Oct 21, 2020 |
| Therapix Biosciences — Investor Presentation (September 2020) | Investor deck | 22 slides | Sep 16, 2020 |
| Therapix Biosciences — Investor Presentation (April 2020) | Investor deck | 15 slides | Apr 22, 2020 |
| Therapix Biosciences — Investor Presentation (February 2019) | Investor deck | 23 slides | Feb 12, 2019 |
| Therapix Biosciences — Seminar TASE June 2017 | Conference | 33 slides | Jun 29, 2017 |
| Therapix Biosciences — IPO Roadshow (March 2017) | IPO roadshow | 21 slides | Mar 20, 2017 |
IPO
Went public as Therapix Biosciences Ltd. Priced at US$6.00 an ADS on Mar 22, 2017.
- Price
- US$6.00 an ADS
- ADSs offered
- 2,000,000 American depositary shares
- Offering size
- US$12 million
- Underwriters' option
- Up to 300,000 more ADSs
- Listing
- TRPX on the Nasdaq Capital Market
- Underwriter
- Laidlaw & Company (UK) Ltd.
- ADSs delivered
- On or about Mar 27, 2017
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 9, 2016 |
| Filed publicly | Nov 4, 2016 |
| Amended 8 times | Newest Mar 20, 2017 |
| Shares registered with an exchange | Mar 21, 2017 |
| Declared effective by the SEC | Mar 21, 2017 |
| Final prospectus, with the price | Mar 22, 2017 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 22, 2017 |
| EFFECT · Notice that a registration is effective | Mar 21, 2017 |
| CERTNAS · Nasdaq's certificate of listing | Mar 21, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 21, 2017 |
| CORRESP · Letter to the SEC | Mar 20, 2017 |
| CORRESP · Letter to the SEC | Mar 20, 2017 |
| UPLOAD · Letter from the SEC | Mar 20, 2017 |
| FWP · Free writing prospectus | Mar 20, 2017 |
| CORRESP · Letter to the SEC | Mar 20, 2017 |
| F-1/A · Registration statement, amended | Mar 20, 2017 |
All 38 filings
Open IPO · From the cover of the final prospectus (424B4) filed Mar 22, 2017
Financials
Annual, in USD
Income statement
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.31M | 2.88M | 1.35M | |||||||
| Cost of revenue | 800.0K | 683.0K | 322.0K | |||||||
| Gross profit | 506.0K | 2.20M | 1.02M | |||||||
| Research and development | 1.71M | 1.64M | 2.80M | 1.99M | 649.0K | 1.64M | 2.71M | 1.94M | 740.0K | -240.0K |
| Selling, general and administrative | 5.03M | 5.97M | 3.78M | 1.90M | 2.47M | |||||
| Operating income | -7.32M | -6.82M | -8.29M | -5.77M | -3.29M | -4.11M | -7.24M | -5.75M | -2.00M | 2.56M |
| Depreciation and amortization | 482.0K | 538.0K | 187.0K | 33.0K | 164.0K | 179.0K | 147.0K | 5.00K | 4.00K | 3.00K |
| EBITDA | -6.83M | -6.28M | -8.10M | -5.74M | -3.13M | -3.93M | -7.09M | -5.75M | -2.00M | 2.57M |
| Interest expense | 353.0K | 1.05M | 2.01M | 21.0K | 872.0K | 676.0K | 121.0K | 491.0K | 8.00K | -9.00K |
| Income before tax | -7.49M | -5.86M | -2.58M | -5.79M | -3.54M | -9.01M | -6.24M | -2.01M | 2.62M | |
| Income tax | -14.0K | 22.0K | 14.0K | -60.0K | ||||||
| Net income | -6.28M | -5.12M | -2.59M | -5.79M | 3.54M | 4.69M | 6.53M | 6.24M | 1.99M | 2.54M |
| Earnings per share, basic | 26.88 | 303.03 | 311.22 | 73.58 | 0.10 | 0.64 | 1.20 | 0.04 | 0.05 | |
| Earnings per share, diluted | 26.88 | 303.03 | 311.22 | 73.58 | 0.11 | 0.64 | 1.20 |
Balance sheet
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.54M | 2.08M | 3.57M | 6.88M | 1.95M | 870.0K | 1.49M | 9.20M | 676.0K | 1.57M |
| Receivables | 10.0K | 22.0K | 77.0K | 2.90M | 594.0K | 75.0K | 404.0K | 278.0K | 117.0K | |
| Inventory | 113.0K | 742.0K | 668.0K | |||||||
| Current assets | 7.50M | 6.45M | 4.51M | 9.82M | 2.55M | 955.0K | 2.43M | 9.50M | 804.0K | |
| Property, plant and equipment | 59.0K | 108.0K | 57.0K | 92.0K | 11.0K | 175.0K | 2.11M | 50.0K | 11.0K | |
| Total assets | 10.3M | 11.2M | 10.6M | 9.92M | 2.56M | 1.15M | 4.56M | 9.57M | 1.25M | |
| Accounts payable | 205.0K | 185.0K | 193.0K | 154.0K | 34.0K | 108.0K | 844.0K | 160.0K | 82.0K | |
| Current liabilities | 1.40M | 1.57M | 4.16M | 1.76M | 1.13M | 1.05M | 4.48M | 1.18M | 672.0K | |
| Shareholders' equity | 8.15M | 7.61M | 6.45M | 8.14M | 1.43M | 14.0K | 185.0K | 8.39M | 573.0K | 1.16M |
| Shares outstanding | 515.6K | 33.7K | 261.5K | 3.09M | 1.04M | 11.4M | 140.3M | 139.9M | 41.0M |
Cash flow
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5.10M | -5.89M | -7.92M | -5.06M | -4.31M | -4.70M | -7.13M | -4.58M | -1.47M | -1.40M |
| Capital spending | -8.00K | -35.0K | -1.00K | -17.0K | -44.0K | -4.00K | -2.00K | |||
| Free cash flow | -7.92M | -5.10M | -4.70M | -7.15M | -4.62M | -1.48M | -1.41M | |||
| Cash from investing | -1.63M | -4.09M | -7.08M | -70.0K | 24.0K | 1.27M | -2.09M | -53.0K | -5.00K | -1.00K |
| Cash from financing | 6.19M | 8.48M | 11.7M | 10.1M | 5.36M | 2.80M | 1.54M | 13.2M | 565.0K | 2.75M |
| Change in cash | -536.0K | -1.50M | -3.30M | 4.93M | 1.08M | -615.0K | -7.71M | 8.52M | -897.0K | 1.42M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EFFECT · Notice that a registration is effective | Nov 20, 2026 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| F-3 · Registration statement | Nov 9, 2026 | Offer document | SEC |
| 6-K/A · Report of a foreign issuer, amended | Nov 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 3, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 26, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 23, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 15, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 15, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 7, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 611 filings. Open Filings
Cap table
Built by 6ix from SciSparc Ltd.’s releases
- Common shares
- 23,073,243
- Fully diluted
- 23,073,243
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 23,073,243 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 23,073,243 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Amitay Weiss Other companies: Clearmind Medicine Inc. (Chairman of the Board · Since at least Nov 5, 2026); Maris-Tech Ltd. (Director · Since at least Mar 18, 2026); Nexera Technologies Ltd (Director · Since at least Mar 18, 2026); ParaZero Technologies Ltd. (Director · Since at least Mar 18, 2026); Quantum X Labs Inc. (Director · Since at least Sep 19, 2022); Nexentis Technologies Inc. (Director · Since at least Aug 26, 2020) | Chairman · Since at least Oct 23, 2025 |
| Liat Sidi Other companies: Polyrizon Ltd. (Director · Since at least Mar 18, 2026); Nexentis Technologies Inc. (Director · Since at least Nov 12, 2023) | Director · Since at least Oct 23, 2025 |
| Oz Adler Other companies: Polyrizon Ltd. (Director · Since at least Mar 31, 2026); Clearmind Medicine Inc. (Director · Since at least Mar 19, 2025) | Chief Executive Officer and Chief Financial Officer · Since at least Aug 19, 2026 |
| Adi Zuloff-Shani Other companies: Clearmind Medicine Inc. (CEO · Since at least Oct 27, 2026) | Chief Technology Officer · Since at least Mar 18, 2026 |
| Moshe Revach Other companies: ParaZero Technologies Ltd. (Director · Since at least May 29, 2026) | Director · Since at least Nov 17, 2026 |
| Alon Dayan | external director · Since at least Mar 18, 2026 |
| Amnon Ben Shay | external director · Since at least Nov 17, 2026 |
| Itschak Shrem | President · Since at least Mar 18, 2026 |
| Lior Vider | Director · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about SciSparc Ltd.